



**DATE:** August 19, 2022  
**TO:** Health Care Providers and Health Care Facilities  
**FROM:** New York State Department of Health

**Guidance on How to Request a Supply of COVID-19 Monoclonal Antibody (mAb) and Oral Antiviral Therapeutics**

Summary:

- This document supersedes the September 18, 2021, September 23, 2021, November 5, 2021, and May 6, 2022 “Guidance on How to Request a Supply of COVID-19 Monoclonal Antibody (mAb) Therapeutics.”
- Requests to the NYS Department of Health for a supply of Evusheld will need to be submitted through the Health Partner Order Portal (HPOP).
- Bebtelovimab is now available commercially through AmerisourceBergen.

This announcement provides updated details on how New York State (NYS) providers can submit requests for a supply of monoclonal antibody (mAb) and/or oral antiviral therapeutics.

As of August 15, 2022, Bebtelovimab is commercially available for purchase and is no longer being allocated by the United States Government (USG). New York State will not be purchasing Bebtelovimab and will no longer be taking any requests for product. Any provider interested in obtaining Bebtelovimab will need to procure this product directly by purchasing it through AmerisourceBergen. The U.S. Department of Health & Human Services (HHS) continues to oversee the state/territory-coordinated distribution system of certain mAb and oral antiviral therapeutics. Each state/territorial Health Department will continue to assign weekly Evusheld and oral antiviral allocations within their jurisdiction based on the allotments provided by HHS. The amount allocated by HHS will be based on population (oral antiviral) or COVID-19 case burden (mAb). This allocation is separate from the Federal Test to Treat and/or Long Term Care Pharmacy program allocations made directly from HHS to participating providers. The mAb therapeutic available is:

1. Evusheld (AstraZeneca)

The oral antivirals affected are:

1. Paxlovid (Pfizer)
2. Renal Paxlovid (Pfizer)
3. Lagevrio (molnupiravir) (Merck)

The NYS Department of Health (Department) will no longer be taking requests for mAb therapeutics from NYS providers through the NYS mAb request form. Evusheld and oral antivirals must be requested directly in HPOP by enrolled providers.

All requests will be reviewed by the Department on a weekly basis prior to making allotments. Once an allotment is made, a provider will be able to view their allotment and shipping information in HPOP. As the State will be allotted a finite amount of COVID-19 therapeutic product each week, providers may not receive the total amount of product they requested. Each provider will receive product based on the supply allotted to the State from HHS. Providers are reminded that while HPOP ordering is always available, all requests are processed and evaluated on a weekly basis before orders are placed. As a result, there may be a delay from the time a request is inputted, and the order is placed.

### **Provider Requirements:**

In order to receive Evusheld and/or oral antiviral product, providers **must** continue to comply with Federal reporting requirements. Courses utilized and courses available for all COVID-19 therapeutics must be reported **every Monday and Thursday** by 11:59 pm in HPOP on days that you are open for business. If a day of reporting is missed, on the next completed report, input the courses available and courses administered. Courses available should be reported as a snapshot in time at the time the reporting is entered and courses administered should be the number administered since the last report, not a cumulative total.

Reporting of inventory and administration of all USG-procured and distributed supply of Bebtelovimab remains a requirement until all USG-procured Bebtelovimab is consumed.

### **How to Request COVID-19 Therapeutics:**

Requests for eligible mAb and oral antiviral product should be submitted through HPOP as per the following directions:

1. Sign in to HPOP.
2. Click the green "Create Order" or "Create External Order" button on the Therapeutics Orders panel at the top left of the Provider screen.
3. Enter the amount of each product you are requesting for that week.

See HPOP Provider User Guide for more detailed instructions.

As a reminder, the amount a provider requests may not be the amount the provider receives. The amount received will be based on the supply allotted to the State from HHS.

### **How to Request Small Volumes of Evusheld:**

Individual providers seeking small quantities of product (1-3 patient courses) can order via:

1. 1-833-EVUSHLD (833-388-7453)
2. [OrderEvusheld.com](https://www.amsbergen.com/OrderEvusheld.com)

For questions regarding small volume ordering, please contact [c19therapies@amerisourcebergen.com](mailto:c19therapies@amerisourcebergen.com).

## How to Purchase Bebtelovimab:

### Existing AmerisourceBergen Accounts:

AmerisourceBergen will sell bebtelovimab to licensed and approved customers such as hospitals, infusion centers, long term care facilities, clinics, etc. However, retail pharmacies will be excluded. For any questions regarding product access, please contact [c19therapies@amerisourcebergen.com](mailto:c19therapies@amerisourcebergen.com).

### Sites Without an AmerisourceBergen Account:

To purchase bebtelovimab, your site must have a fully-vetted commercial account with AmerisourceBergen. To initiate the account creation process, please contact AmerisourceBergen at the following email address: [asdaccountsetup@amerisourcebergen.com](mailto:asdaccountsetup@amerisourcebergen.com).

If you have any questions regarding the commercial purchase of bebtelovimab, please contact AmerisourceBergen at [c19therapies@amerisourcebergen.com](mailto:c19therapies@amerisourcebergen.com).

### **Deadlines:**

**All requests must be submitted using the process above every week by Monday, 5:00PM EST.** Orders will not be reviewed until after Monday at 5pm and all orders have been received. These requests will be reviewed that same week and entered in HPOP by the Friday deadline for each weekly cycle. Sites will receive an email from the HPOP system letting them know the amount of mAb and/or oral antiviral product that has been ordered so they can prepare for delivery.

Please visit the Department's *Monoclonal Antibody (mAb) Therapeutics: Information for Providers* website: <https://coronavirus.health.ny.gov/monoclonal-antibody-therapeutics> and the *Oral Antivirals* website: <https://coronavirus.health.ny.gov/oral-antivirals> for further information. For questions, please send an email to [COVID19therapeutics@health.ny.gov](mailto:COVID19therapeutics@health.ny.gov).